|
|
|
| Analysis of related literature based on CiteSpace leukoencephalopathy |
| WEI Nina XU Manman PAN Juhua HUANG Shijing▲ WANG Yanyun |
| New Drug Research and Development Laboratory, Guang′anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China |
|
|
|
Abstract Objective To explore the main research directions and hot pots of leukoencephalopathy by visual analysis of clinical neuroscience literature in the past 15 years. Methods The literature related to leukoencephalopathy in SCI-E from January 2004 to December 2018 in Web of Science was searched with the method of cis search. CiteSpaceV 5.4.R3 was applied to analyze the authors, research institutions, national cooperation relations, keywords co-occurrence analysis, and to visually analyze the co-citation of their literature and journals. Results A total of 3181 papers were obtained, with an average annual volume of nearly 212 papers. The number of published articles on the whole showed an upward trend, reaching the highest citation level in the past 15 years in 2017. The author with the highest amount of published articles was van der Knaap MS. The leading countries in this field were the United States, Germany and Italy, which produced more literature and cooperate closely. The Mayo clinic and the university of Munich were leading authorities in the field. The hot keywords were nachizumab, leukodystrophy, leukoencephalopathy, subcortical infarction, disappeared white matter, etc., which could form 8 clusters. The journal with the highest frequency of citation was Neurology. The most frequency of citation was the paper published by Bloomgren G et al., on the risk of progressive multiform leukoencephalopathy associated with natazumab. The highest ranking central literature was an literature by Gorelik L et al. published in Ann Neurol in 2010 on the effect of anti-JC virus antibodies on risk stratification of leukoencephalopathy. Conclusion The application of CiteSpace in the literature analysis of clinical neuroscience of leukoencephalopathy in the past 15 years shows the current countries and institutions of cooperation，reveals the hot spots and directions of research，and has important reference value for the in-depth study of leukoencephalopathy.
|
|
|
|
|
|
[1] 杨梦歌，郑超，刘玲玲，等.MRI上病灶呈双侧对称分布的脑白质病[J].中风与神经疾病杂志，2018，35（11）：1035-1041.
[2] 姚生.提高对不同类型遗传性脑小血管病的认识[J].中华老年心脑血管病杂志，2019，21（9）：897-900.
[3] 高亚军，屈永才.缺血性脑白质病的临床研究[J].延安大学学报：医学科学版，2018，16（2）：90-93.
[4] 韩露露，黄世敬.缺血性脑白质病的中医治疗进展[J].辽宁中医杂志，2019，46（4）：866-868.
[5] van der Knaap MS，Bugiani M，Mendes MI，et al. Biallelic variants in LARS2 and KARS cause deafness and（ovario）leukodystrophy [J]. Neurology，2019，92（11）：e1225-e1237.
[6] Gold R，Kappos L，Arnold DL，et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis [J]. N Engl J Med，2012，367（12）：1098-1107.
[7] Chabriat H，Hervé D，Duering M，et al. Predictors of clinical worsening in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy：prospective cohort study [J]. Stroke，2016，47（1）：4-11.
[8] Dichgans M. Dementia risk after transient ischaemic attack and stroke [J]. Lancet Neurol，2019，18（3）：223-225.
[9] Vanderver A，Simons C，Helman G，et al. Whole exome sequencing in patients with white matter abnormalities [J]. Ann Neurol，2016，79（6）：1031-1037.
[10] Polman CH，Reingold SC，Banwell B，et al. Diagnostic criteria for multiple sclerosis：2010 revisions to the McDonald criteria [J]. Annals of neurology，2011，69（2）：292-302.
[11] Kappos L，Bar-Or A，Cree BAC，et al. Siponimod versus placebo in secondary progressive multiple sclerosis（EXPAND）：a double-blind，randomised，phase 3 study [J]. Lancet，2018，391（10127）：1263-1273.
[12] Rudick RA，Cohen JA. Aspects of multiple sclerosis that relate to clinical trial design and treatment [M]. //Mult.Scler.Ther.CRC Press，2019：31-49.
[13] Van Assche G，Van Ranst M，Sciot R，et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn′s disease [J]. N Engl J Med，2005，353（4）：362-368.
[14] Kleinschmidt-DeMasters BK，Donson A，Foreman NK，et al. H3 K27M mutation in gangliogliomas can be associated with poor prognosis [J]. Brain Pathol，2017，27（6）：846-850.
[15] Hinchey J，Chaves C，Appignani B，et al. A reversible posterior leukoencephalopathy syndrome [J]. New Engl J Med，1996，334（8）：494-500.
[16] Berger JR. Classifying PML risk with disease modifying therapies [J]. Mult Scler Relat Disord，2017，12：59-63.
[17] Bloomgren G，Richman S，Hotermans C，et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy [J]. N Engl J Med，2012，366（20）：1870-1880.
[18] Gorelik L，Lerner M，Bixler S，et al. Anti-JC virus antibodies：implications for PML risk stratification [J]. Ann Neurol，2010，68（3）：295-303.
[19] Dowling E，Hamilton III GS，Janus J. Mayo Clinic，Roch-ester，MN，United States [J]. Handbook of Tissue Engineering Scaffolds：Volume One，2019：387.
[20] Westphalen CB，Preinfalk A，Kruger S，et al. Neurotrophic tropomyosin receptor kinase（NTRK）and nerve growth factor（NGF）are not expressed in Caucasian patients with biliary tract cancers：pooled data from three independent cohorts [J]. Clin Transl Oncol，2019，21（8）：1108-1111. |
|
|
|
